详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

KRASG12C Inhibitors in Non-Small Cell Lung Cancer: A Review

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Division of Thoracic Tumor Multimodality Treatment and Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China. [2]Laboratory of Clinical Cell Therapy, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China. [3]Laboratory of Human Disease and Immunotherapies, West China Hospital, Sichuan University, Chengdu, People's Republic of China. [4]Institute of Inflammation and Immunology (I3), Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, People's Republic of China.

出处：

DOI：

ISSN：

关键词： KRAS G12C non-small cell lung cancer brain metastases

摘要：

Rat sarcoma virus (RAS) GTPase is one of the most important drivers of non-small cell lung cancer (NSCLC). RAS has three different isoforms (Harvey rat sarcoma viral oncogene homolog [HRAS], Kirsten rat sarcoma viral oncogene homolog [KRAS] and Neuroblastoma ras viral oncogene homolog [NRAS]), of which KRAS is most commonly mutated in NSCLC. The mutated KRAS protein was historically thought to be "undruggable" until the development of KRASG12C inhibitors. In this review, from the aspect of brain metastasis, we aim to provide an overview of the advances in therapies that target KRASG12C, the limitations of the current treatments, and future prospects in patients with KRAS p.G12C mutant NSCLC.© 2024 Tang et al.

基金：

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2023]版：

大类 | 4 区医学

小类 | 3 区生物工程与应用微生物 4 区肿瘤学

最新[2023]版：

大类 | 4 区医学

小类 | 3 区生物工程与应用微生物 4 区肿瘤学

第一作者：

第一作者机构： [1]Division of Thoracic Tumor Multimodality Treatment and Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China. [2]Laboratory of Clinical Cell Therapy, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China.

通讯作者：

通讯机构： [1]Division of Thoracic Tumor Multimodality Treatment and Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China. [2]Laboratory of Clinical Cell Therapy, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China. [*1]West China Hospital, West China School of Clinical Medicine, Sichuan University, 37, Guoxue Lane, Chengdu, 610041

推荐引用方式(GB/T 7714)：

APA：

MLA：

KRASG12C Inhibitors in Non-Small Cell Lung Cancer: A Review

文献详情

相关文献